Welcome to our dedicated page for Rapid Micro Biosystems news (Ticker: RPID), a resource for investors and traders seeking the latest updates and insights on Rapid Micro Biosystems stock.
Rapid Micro Biosystems, Inc. (RPID) provides automated microbial quality control solutions for pharmaceutical manufacturers and life sciences organizations. This page aggregates official announcements, operational updates, and strategic developments impacting the company’s market position.
Access timely updates on RPID’s Growth Direct platform enhancements, regulatory compliance milestones, and industry partnerships. Investors will find earnings reports, management commentary, and manufacturing efficiency initiatives critical for evaluating the company’s performance in microbial detection automation.
Key updates include product launch details, intellectual property developments, and operational expansions within regulated healthcare markets. Content reflects RPID’s focus on reducing contamination risks and improving testing workflows through automated solutions.
Bookmark this page for structured access to RPID’s latest news stream, including analysis of market trends affecting quality control automation demand. Verify time-sensitive decisions against primary source materials linked where available.
Rapid Micro Biosystems (Nasdaq: RPID) is set to release its first quarter 2023 financial results on May 5, 2023, before market opening. The release will be accompanied by a webcast conference call at 8:30 AM EST, which will be accessible for replay for one year. The company specializes in automation solutions that enhance the manufacturing processes for healthcare products, including vaccines and biologics. Their Growth Direct System modernizes microbial quality control testing for pharmaceutical manufacturers, aiming to improve efficiency and compliance. Headquartered in Lowell, Massachusetts, Rapid Micro also has global operations in Europe.
Rapid Micro Biosystems (Nasdaq: RPID) reported fourth quarter 2022 commercial revenue of $4.4 million, down from $5.2 million in Q4 2021. For full year 2022, total revenue was $17.1 million, a decline from $23.2 million in 2021. However, the recurring commercial revenue reached $11.0 million, a significant growth of 40%. The company forecasted 2023 revenue of at least $22.0 million, reflecting an approximate 30% increase. Notably, they maintained $138.4 million in cash with no debt. The net loss for Q4 2022 was $16.4 million, worsening from $14.6 million in Q4 2021.
Rapid Micro Biosystems (Nasdaq: RPID) announced participation in the Cowen 43rd Annual Health Care Conference in Boston on March 8, 2023. The Company's President and CEO Rob Spignesi, along with CFO Sean Wirtjes, will engage in a 30-minute Q&A session starting at 9:10 a.m. Eastern Time. A live webcast will be available on the Company’s investor relations website and can be replayed for 90 days post-event. Rapid Micro Biosystems specializes in automation solutions for healthcare product manufacturing, enhancing microbial quality control with its Growth Direct System. This innovation supports faster results, greater accuracy, and compliance in the production of biologics and vaccines.
Rapid Micro Biosystems (Nasdaq: RPID) will announce its fourth quarter and full year 2022 financial results on March 3, 2023, before market opening. A webcast conference call is scheduled for 8:30 a.m. EST on the same day, with live access via the company's website. The company specializes in automation solutions for the healthcare sector, enhancing the manufacturing and quality control of products such as biologics and vaccines. Their flagship Growth Direct System facilitates faster, more accurate microbial quality control testing, improving operational efficiency and compliance in pharmaceutical manufacturing.
FAQ
What is the current stock price of Rapid Micro Biosystems (RPID)?
What is the market cap of Rapid Micro Biosystems (RPID)?
